synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
IGF1 is a primary mediator of the effects of growth hormone (GH). Growth hormone is made in the anterior pituitary gland, released into the bloodstream, and then stimulates the liver to produce IGF1. IGF1 then stimulates systemic body growth, and has growth-promoting effects on almost every cell in the body, especially skeletal muscle, cartilage, bone, liver, kidney, nerve, skin, hematopoietic, and lung cells. In addition to its insulin-like effects (insulin being the main anabolic hormone in the body), IGF1 can also regulate cellular DNA synthesis. IGF1 binds to at least two cell surface receptor tyrosine kinases: the IGF1 receptor (IGF1R), and the insulin receptor. Its primary action is mediated by binding to its specific receptor, IGF1R, which is present on the surface of several cell types in a multitude of tissues. Binding to the IGF1R initiates intracellular signaling. IGF1 is one of the most potent natural activators of the Akt signaling pathway, a stimulator of cell growth and proliferation, and a potent inhibitor of programmed cell death. The IGF1 receptor and insulin receptor are two closely related members of a transmembrane tetrameric tyrosine kinase receptor family. They control vital brain functions, such as survival, growth, energy metabolism, longevity, neuroprotection and neuroregeneration.
=== Routes for topical drug administration === In general, there are three possible routes for drug administration into or across the skin. The first one is the transcellular route, where the drugs are required to pass through both lipid matrix and dead corneocytes of the stratum corneum. The second one is the intercellular route, where the drugs only have to pass through lipid domains between corneocytes. The third one is the trans-appendageal route, where the drugs are transported by hair follicles, sebaceous glands, or sweat glands. The most common route for drug delivery into the skin is the intercellular route. Multiple steps are involved.
Chemical data, Clinical data and Molecular biology/biochemistry data. The database contains 220,945 metabolite entries including both water-soluble and lipid soluble metabolites. Additionally, 8,610 protein sequences (enzymes and transporters) are linked to these metabolite entries. Each MetaboCard entry contains 130 data fields with 2/3 of the information being devoted to chemical/clinical data and the other 1/3 devoted to enzymatic or biochemical data. The version 3.5 of the HMDB contains >16,000 endogenous metabolites, >1,500 drugs and >22,000 food constituents or food metabolites. This information, available at the Human Metabolome Database and based on analysis of information available in the current scientific literature, is far from complete. In contrast, much more is known about the metabolomes of other organisms. For example, over 50,000 metabolites have been characterized from the plant kingdom, and many thousands of metabolites have been identified and/or characterized from single plants. Each type of cell and tissue has a unique metabolic 'fingerprint' that can elucidate organ or tissue-specific information. Bio-specimens used for metabolomics analysis include but not limit to plasma, serum, urine, saliva, feces, muscle, sweat, exhaled breath and gastrointestinal fluid. The ease of collection facilitates high temporal resolution, and because they are always at dynamic equilibrium with the body, they can describe the host as a whole.
Sources: en.wikipedia.org
In Ireland, eGates are available at Dublin Airport for arrivals at Terminal 1 (Piers 1 and 2) and Terminal 2 and, in addition to Irish and British citizens, they are currently available to citizens of Switzerland and the European Economic Area with electronic passports aged 18 or over though there are proposals to extend the service to non-European citizens. Irish passport cards can be used at eGates in Dublin Airport. Caribbean Community: CARIPASS is a voluntary travel card programme that will provide secure and simple border crossings for citizens and legal residents of participating Caribbean Community jurisdictions. The CARIPASS initiative is coordinated by the Implementation Agency for Crime and Security (CARICOM IMPACS), and seeks to provide standardised border control facilities within participating Caribbean communities. CARIPASS is accepted as a valid travel document within and between participating member states and will allow cardholders to access automated gate facilities at immigration checkpoints that will use biometric technology to verify the user. China: Mainland China: Residents in the PRC, both Chinese citizens and foreign residents (not tourists), can use the Chinese E-Channel after registration, which is done at the border, before leaving the Mainland. Chinese citizens with Hong Kong or Macau Permanent Residence can use their Home Return Permit instead of their passport to enter and leave the Mainland.
The following is a timeline of the second presidency of Donald Trump during the fourth and last quarter of 2025, from October 1, 2025, to December 31, 2025. To navigate between quarters, see timeline of the Donald Trump presidencies.
In July 2010, Xinhua reported that authorities had seized 64 tonnes of dairy product contaminated with melamine from Dongyuan Dairy Factory, in Minhe County, in Qinghai, after authorities in Gansu discovered the contaminated powdered milk. Approximately 38 tonnes of raw materials had been purchased from Hebei, raising the possibility that traders had bought tainted milk that was supposed to have been destroyed after the 2008 scandal. Police have detained the owner and production director of the factory. Powdered milk produced in the plant was mainly sold in Zhejiang and Jiangsu, with only a small amount sold in Qinghai. Also, in Jilin, authorities were testing samples of suspect powdered milk produced in Heilongjiang. At the end of June 2010, Beijing lowered the minimum protein level for raw milk, from 2.955 to 2.8%, to discourage dairy farmers from attempting to falsify the passing of protein tests. Wu Heping, secretary general of the Heilongjiang Dairy Industry Association noted that between 75% and 90% of raw milk in some provinces had failed to reach the old protein level standard (in place since 1986) in 2007 and 2008. He said that the new standard reflected "the reality of the domestic dairy farm industry". However, Guangzhou dairy industry association president Wang Dingmian stated that this alone would not remove the incentive for adulteration, because milk price still depends on protein content.
Helton is one of only two Hall-of-Famers to have played for the Rockies (the other being Larry Walker, who was in the class of 2020), and is the only MLB Hall-of-Famer to have played his entire career for the Rockies.
Sources: en.wikipedia.org
=== Drug design === New design of anti-bacterial medications is of continuing importance in scientific research as bacterial antibiotic resistance to common antibiotics increases. A specific metabolic protein that uses FAD (Complex II) is vital for bacterial virulence, and so targeting FAD synthesis or creating FAD analogs could be a useful area of investigation. Already, scientists have determined the two structures FAD usually assumes once bound: either an extended or a butterfly conformation, in which the molecule essentially folds in half, resulting in the stacking of the adenine and isoalloxazine rings. FAD imitators that are able to bind in a similar manner but do not permit protein function could be useful mechanisms of inhibiting bacterial infection. Alternatively, drugs blocking FAD synthesis could achieve the same goal; this is especially intriguing because human and bacterial FAD synthesis relies on very different enzymes, meaning that a drug made to target bacterial FAD synthase would be unlikely to interfere with the human FAD synthase enzymes.
Mescaline is used recreationally, spiritually, and medically. It is typically taken orally. The drug is used as a psychedelic at doses of 100 to 1,000 mg orally. Low doses are 100 to 200 mg, an intermediate or "good effect" dose is 500 mg, and a high (ego-dissolution) dose is 1,000 mg. However, doses of 800 mg and above orally are not well-tolerated due to side effects like severe nausea and vomiting. In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin listed a dose range of 200 to 400 mg as the sulfate salt and 178 to 356 mg as the hydrochloride salt. Microdosing involves the use of daily mescaline doses of less than 75 mg. Mescaline has also been studied via intravenous injection, with assessed doses in the range of 500 to 750 mg as the sulfate salt. In addition to pure form, mescaline is used in the form of cacti such as peyote and the San Pedro cactus. Doses when mescaline is used in the form of fresh or dried cacti have also been described. In traditional peyote preparations, the top of the cactus is cut off, leaving the large tap root along with a ring of green photosynthesizing area to grow new heads. These heads are then dried to make disc-shaped buttons. Buttons are chewed to produce the effects or soaked in water to drink. However, the taste of the cactus is bitter, so modern users will often grind it into a powder and pour it into capsules to avoid having to taste it. The average 76 mm (3.0 in) peyote button contains about 25 mg mescaline. However, another source states that there is about 45 mg mescaline per peyote button on average.
Both lancelets and lampreys have a primitive but functional interferon system that responds to their versions of interferons by upregulating gene similar to the well-known interferon-stimulated genes (LSGs) of land animals. The lamprey interferon receptor has also been identified as a heterodimer of the cytokine receptor family B (CRFB) family, much like in jawed vertebrates. By comparing the genome organizations of jawed fish, jawless fish, and lancelet, it was found that interferons arose by a duplication of interleukin 10 in a chordate ancestor to the vertebrates and the lancelets. By the time the bony fish (e.g. teleosts, tetrapods including humans) diverged from the cartilaginous fish (e.g. sharks), the duplication and specialization of interferon into types I, II (gamma), III (lambda), and IV had been complete. (This is known because types I, II, IV have been found in tetrapods, teleosts, and sharks, and that type III has been found in tetrapods and sharks.) Mammals, actually amniotes in general, are unlike the rest of the animal kingdom in that most of their type I IFNs are intronless, and are placed in a position not colinear with the other vertebrates. This is because the original type I IFN gene was copied in an intronless form (possibly by a retrotransposon acting on mRNA) to a new location between HACD4 and MTAP in a common ancestor of the amniotes, followed by a loss of the ancestral version.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.